(Q34317476)

1 August 2017

1 reference

title

In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature (English)

1 reference

1 August 2017

1 reference

Espinel-Ingroff A

1

1 reference

1 August 2017

Boyle K

series ordinal

2

1 reference

1 August 2017

Sheehan DJ

series ordinal

3

1 reference

1 August 2017

1 January 2001

1 reference

1 August 2017

15

1 reference

inferred from page(s)

published in

Mycopathologia

1 reference

1 August 2017

150

1 reference

1 August 2017

3

1 reference

1 August 2017

101-115

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1010954803886

1 August 2017

0 references

cites work

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

1 reference

12 December 2020

In vitro activity of voriconazole against selected fungi

1 reference

12 December 2020

In vitro evaluation of voriconazole against some clinically important fungi

1 reference

12 December 2020

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

1 reference

12 December 2020

High prevalence of antifungal resistance in Candida spp. from patients with AIDS.

1 reference

12 December 2020

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

1 reference

12 December 2020

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

12 December 2020

Organism-dependent fungicidal activities of azoles

1 reference

12 December 2020

In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp

1 reference

12 December 2020

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

1 reference

12 December 2020

In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole

1 reference

12 December 2020

Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

1 reference

12 December 2020

In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin

1 reference

12 December 2020

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

1 reference

12 December 2020

In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.

1 reference

12 December 2020

In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

1 reference

12 December 2020

Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans

1 reference

12 December 2020

In vitro activity of voriconazole against Candida species

1 reference

12 December 2020

In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates

1 reference

12 December 2020

Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

1 reference

12 December 2020

1 reference

12 December 2020

Resistant candidiasis.

1 reference

12 December 2020

The Emerging Role of Fusarium Infections in Patients with Cancer

1 reference

12 December 2020

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

1 reference

12 December 2020

Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.

1 reference

12 December 2020

In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species

1 reference

12 December 2020

In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.

1 reference

12 December 2020

Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species

1 reference

12 December 2020

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

1 reference

12 December 2020

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

1 reference

12 December 2020

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

1 reference

12 December 2020

Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.

1 reference

12 December 2020

Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease

1 reference

12 December 2020

In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa

1 reference

12 December 2020

Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species

1 reference

12 December 2020

Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates

1 reference

12 December 2020

Effects of voriconazole on Candida glabrata in vitro

1 reference

12 December 2020

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

1 reference

12 December 2020

Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery

1 reference

12 December 2020

Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

1 reference

12 December 2020

Amphotericin B: 30 years of clinical experience

1 reference

12 December 2020

In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection

1 reference

12 December 2020

Itraconazole resistance in Aspergillus fumigatus

1 reference

12 December 2020

Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

1 reference

12 December 2020

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

1 reference

12 December 2020

Invasive aspergillosis caused by Aspergillus ustus: case report and review

1 reference

12 December 2020

Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility

1 reference

12 December 2020

In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications

1 reference

12 December 2020

Disseminated Aspergillus ustus infection following cardiac surgery

1 reference

12 December 2020

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

1 reference

12 December 2020

Lipid formulations of amphotericin B: clinical efficacy and toxicities

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1010954803886

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference